logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Trick or Trade

Rhythm Pharmaceuticals & Akero Therapeutics: On the Morning of September 15, 2022

Rhythm Pharmaceuticals Rhythm Pharmaceuticals ( RYTM) : After soaring, based on great scientific and drug performance in treating genetic obesity, the selloff of the stock has occurred today after the firm’s announcement and pricing of its public offering of 4.8M...

Read More

September 15, 2022

0

Our Eyes Are on Reata Pharmaceuticals Today

Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals ( RETA ) announced a setback of its chronic kidney disease product known as bardoxolone. The failure of this drug occurred after Reata's product Skyclaris was FDA approved for the treatment of Friedrich's...

Read More

May 25, 2023

0

Searching for Biotech Firms with Novel Drugs That Reached Clinical-Stage or Were Granted Early Fast Track Designation

Searching for Biotech Firms The search is for firms biotech firms that have reached clinical stage with novel products that had some earlier, encouraging test results, whose technologies and lead products must have demonstrated  improvement over current treatments of devastating...

Read More

October 28, 2022

0

What We Learned This Morning

Dear Subscribers, This is what we learned this morning: FTX: we learned about the arrest of Sam Bankman Fried and about the firm’s hearing today. We heard from several sources that FTX has been a house of cards built on...

Read More

December 13, 2022

0

Promising Stocks in the First Two Trading Days of 2023

The Stock Market in the New Year It is still too early to tell how the stock market will perform in 2023. However, o n Tuesday January 3, 2023 (the first market trading day in 2023), most biotech stocks plummeted,...

Read More

January 4, 2023

0

Stocks Outperforming Today

January 5, 2023 In Today's Down Market the stocks that are outperforming are as follows: Reata Pharmaceuticals ( RETA ) bluebird bio Inc ( BLUE ) And Vertex Pharmaceuticals ( VRTX ) ...

Read More

January 5, 2023

0

Could We Soon Have a Specific Treatment for the Rare Disease IgA Nephritis?

It's Time to Remind About Travere Therapeutics The time has come to remind that the U.S. FDA is reviewing Travere Therapeutics’ ( TVTX ) New Drug Application ( NDA ) under Subpart H for accelerated approval of sparsentan for IgA...

Read More

February 2, 2023

0

Xenon Pharmaceuticals: A Newly Selected Clinical-Stage Firm. See Also: Recently Selected Clinical Stage Firms

Xenon Pharmaceuticals Xenon Pharmaceuticals ( XENE ) - a clinical stage biopharmaceutical company developing novel  treatments aimed at improving the lives of patients with neurological disorders. The firm is advancing its neurology pipeline to address diseases with unmet medical need. The...

Read More

February 7, 2023

0

Endogena Therapeutics: Treating Retinitis Pigmentosa and Other Devastating Degenerative Diseases

Endogena Therapeutics The US FDA designated Fast Track development program for the investigation of Endogena Therapeutics' product EA-2353 for the treatment of Retinitis Pigmentosa ( RP ). The Fast Track is a process designed to enable patients to benefit earlier...

Read More

February 8, 2023

0

The FDA Approval of Biogen's Alzheimer's Disease Drug and How Cassava Sciences Alzheimer's Disease Drug Differs

Biogen Product Adulelm Approved for Alzheimer's Disease The latest news regarding Alzheimer’s disease is that of the FDA’s approval of Biogen Inc's ( BIIB ) Alzheimer disease product Adulelm (aducanumab). Although the approval seemed to be great news for Biogen...

Read More

June 12, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 10
  • 11
  • 12
  • ...
  • 16
  • 17
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy